Table 3.
Epidemiology and outcomes of acute revascularization therapies during the first wave of the COVID-19 pandemic compared to the three months before (A) pre-COVID period: December 2019 until February 2019 and (B) COVID period: March 2020 until May 2020
| Variables | Monthly numbers | |||
|---|---|---|---|---|
| Pre-COVID (A) | COVID period (B) | Relative change (%) | p value | |
| Stroke hospitalizations (mean, ± SD) | 42.5 (1.1) | 35.8 (4.0) | − 15.8 | 0.025 |
| IVT (mean, ± SD) | 9.3 (4.2) | 8 (3.9) | − 14.0 | 0.130 |
| Proportion IVT (%) | 21.8% | 22.2% | + 0.4 | 0.440 |
| Proportion IVT early window (%) | 86.2% | 88% | + 1.8 | 0.250 |
| EVT (mean, ± SD) | 7 (4.4) | 6.1 (3.9) | − 12.9 | 0.255 |
| Proportion EVT (%) | 16.3% | 17% | + 0.7 | 0.460 |
| Door-to-needle time | ||||
| IVT early window (mean, ± SD; min) | 36.2 (5.4) | 39.1 (5.6) | + 7.0 | 0.135 |
| IVT late window or unknown onset (mean, ± SD; min) | 69.2 (29.1) | 129.1 (89.1) | + 86.6 | 0.255 |
| Door-to-groin time (mean, ± SD; min) | 66.0 (10.3) | 67.9 (2.1) | + 3.0 | 0.255 |
| mRS 3 months (median) | 2 | 2 | n/a | 0.455 |
Early time window was defined as presentation in the hospital in the first 4.5 h after symptom onset
IVT intravenous thrombolysis, EVT endovascular treatment, mRS modified Rankin’ Scale (for neurological disability)